Biocon secures earliest licensed launch dates for Pebrilzo® (bPertuzumab) following global patent settlement with Genentech

Biocon has entered into a global settlement and license agreement with Genentech, securing earliest licensed launch dates for Pebrilzo®, its biosimilar to the reference product Perjeta® (Pertuzumab).

Biocon and Genentech executed the patent settlement agreement to resolve all pending disputes between the companies, including in the US, Canada, and other jurisdictions.

This global patent settlement and license agreement enables Biocon to launch Pebrilzo® in Q1 of calendar year (CY) 2027 in the European Union and UK, Q3 of CY 2028 in the U.S., and in CY 2026-2028 in other Rest of the World (RoW) countries or earlier in certain circumstances.

Pebrilzo® is a biosimilar medicinal product and the active substance is Pertuzumab, a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2. Pebrilzo® is used for the treatment of HER2-positive breast cancer across multiple disease stages.